恩替卡韦治疗失代偿期乙型肝炎肝硬化的临床疗效观察

Clinical Curative Effect of Entecavir in the Treatment of Decompensated Hepatitis B Cirrhosis

目的观察恩替卡韦治疗失代偿期乙型肝炎肝硬化的临床疗效。方法选取我院2015年1月至2016年12月收治的80例失代偿期乙型肝炎肝硬化患者,依据治疗方法的不同分为实验组和对照组各40例。对照组给予常规内科治疗,实验组在对照组基础上给予恩替卡韦治疗。比较两组治疗后12周、 24周、 48周、 72周的肝功能指标、 HBV-DNA定量及Child-Pugh评分,记录患者的生存情况。结果治疗后12周、 24周、 48周、 72周,两组的ALT、 TBIL、 HBV-DNA、 Child-Pugh评分均显著下降,且实验组的ALT、 TBIL、 HBV-DNA、 Child-Pugh评分均显著低于对照组,差异均有统计学意义(P <0.05)。实验组的HBV转阴率显著高于对照组(P <0.05)。结论恩替卡韦治疗失代偿期乙型肝炎肝硬化能够显著改善患者的肝功能,提高长期生存率,值得临床推广。

Objective To observe the clinical curative effect of entecavir in the treatment of decompensated hepatitis B cirrhosis.Methods 80 cases of patients with decompensated hepatitis B cirrhosis admitted to our hospital from January 2015 to December 2016 were selected and divided into experimental group and control group according to the different treatment methods,with 40 cases in each group.The control group was given routine medical treatment,while the experimental group was treated with entecavir on the basis of the control group.The liver function indicators,HBV-DNA quantification and Child-Pugh scores 12 weeks,24 weeks,48 weeks and 72 weeks after treatment were compared between the two groups.Patients’ survival conditions were recorded.Results 12 weeks,24 weeks,48 weeks and72 weeks after treatment,the ALT,TBIL,HBV-DNA and Child-Pugh scores of the two groups significantly decreased(P<0.05),and the ALT,TBIL,HBV-DNA and Child-Pugh scores of the experimental group were significantly lower than those of the control group(P<0.05).The HBV negative rate of the experimental group was significantly higher than that of the control group(P<0.05).Conclusions Entecavir in the treatment of decompensated hepatitis B cirrhosis can significantly improve the liver function of patients and improve long-term survival rate,which is worthy of clinical promotion.